These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 32117306)

  • 1. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
    Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
    Front Immunol; 2020; 11():181. PubMed ID: 32117306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect.
    Couturier M; Lamarthée B; Arbez J; Renauld JC; Bossard C; Malard F; Bonnefoy F; Mohty M; Perruche S; Tiberghien P; Saas P; Gaugler B
    Leukemia; 2013 Jul; 27(7):1527-37. PubMed ID: 23399894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.
    Li J; Heinrichs J; Haarberg K; Semple K; Veerapathran A; Liu C; Anasetti C; Yu XZ
    J Immunol; 2015 Jul; 195(2):717-25. PubMed ID: 26048147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
    Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
    Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
    Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
    Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice.
    Semple K; Yu Y; Wang D; Anasetti C; Yu XZ
    Biol Blood Marrow Transplant; 2011 Mar; 17(3):309-18. PubMed ID: 21224010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icariin protects against acute graft-versus-host disease while preserving graft-versus-leukemia activity after allogeneic hematopoietic stem cell transplantation.
    Su L; Wei ZF; Pi CC; Qin TX; Song F; Zhang YW; Gao SJ
    Phytomedicine; 2024 Sep; 132():155901. PubMed ID: 39067193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
    Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
    Front Immunol; 2018; 9():3104. PubMed ID: 30733722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease.
    Yang J; Ramadan A; Reichenbach DK; Loschi M; Zhang J; Griesenauer B; Liu H; Hippen KL; Blazar BR; Paczesny S
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30694220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.
    Daenthanasanmak A; Iamsawat S; Chakraborty P; Nguyen HD; Bastian D; Liu C; Mehrotra S; Yu XZ
    Blood; 2019 Jan; 133(3):266-279. PubMed ID: 30514750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-12/IL-18-preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation.
    Song Y; Hu B; Liu Y; Jin Z; Zhang Y; Lin D; Zhu Y; Lei L; Gong H; Mei Y; Teo HY; Wu D; Liu H
    Eur J Immunol; 2018 Apr; 48(4):670-682. PubMed ID: 29282719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Lkb1 impairs Treg function and stability to aggravate graft-versus-host disease after bone marrow transplantation.
    Su X; Wang Q; Guo W; Pei X; Niu Q; Liu M; Liu Y; Chen S; Feng S; He Y; Yang D; Zhang R; Ma Q; Zhai W; Pang A; Wei J; Huang Y; Luo Y; Han M; Feng X; Jiang E
    Cell Mol Immunol; 2020 May; 17(5):483-495. PubMed ID: 31664223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
    Yao Y; Wang L; Zhou J; Zhang X
    J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of regulatory T cells on the graft-versus-leukemia effect.
    Pacini CP; Soares MVD; Lacerda JF
    Front Immunol; 2024; 15():1339318. PubMed ID: 38711496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
    Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
    Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.
    Choi J; Ritchey J; Prior JL; Holt M; Shannon WD; Deych E; Piwnica-Worms DR; DiPersio JF
    Blood; 2010 Jul; 116(1):129-39. PubMed ID: 20424188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation.
    Colonna L; Florek M; Leveson-Gower DB; Sega EI; Baker J; Smith AT; Negrin RS
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1557-65. PubMed ID: 23921175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.